Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Wall Street Zen

Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.

Several other analysts have also recently commented on CGEM. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. TD Cowen raised shares of Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Cullinan Therapeutics in a report on Monday, August 17th. Wedbush upped their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Finally, BTIG Research increased their price target on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.00.

Cullinan Therapeutics Stock Performance

Shares of CGEM opened at $20.40 on Friday. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $23.19. The company has a market capitalization of $1.31 billion, a PE ratio of -6.58 and a beta of 0.02. The stock has a fifty day moving average of $19.51 and a two-hundred day moving average of $16.47.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). As a group, equities research analysts forecast that Cullinan Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 30,000 shares of Cullinan Therapeutics stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $20.26, for a total transaction of $607,800.00. Following the transaction, the insider directly owned 162,844 shares of the company’s stock, valued at $3,299,219.44. The trade was a 15.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 46,000 shares of company stock valued at $922,920 in the last 90 days. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Cullinan Therapeutics in the second quarter valued at approximately $95,289,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Cullinan Therapeutics during the second quarter valued at approximately $28,039,000. California State Teachers Retirement System lifted its position in shares of Cullinan Therapeutics by 2,311.4% during the second quarter. California State Teachers Retirement System now owns 733,007 shares of the company’s stock worth $13,348,000 after purchasing an additional 702,610 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Cullinan Therapeutics by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after purchasing an additional 57,259 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new position in shares of Cullinan Therapeutics in the second quarter valued at $12,828,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG raised its price target to $40 and reaffirmed a Buy rating. The new target implies approximately 96% upside from the referenced $20.40 price, signaling that the analyst believes the REZILIENT3 data and Cullinan’s broader pipeline remain undervalued. BTIG price-target report
• Positive Sentiment: REZILIENT3 delivered a six-month median progression-free-survival benefit. Zipalertinib combined with chemotherapy outperformed chemotherapy alone in first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancer, providing potentially important support for the drug’s regulatory and commercial prospects. REZILIENT3 Phase 3 results
• Neutral Sentiment: Cullinan held a virtual analyst and investor event to discuss the interim REZILIENT3 analysis presented at the IASLC 2026 World Conference on Lung Cancer. The event gives management an opportunity to explain the data, address investor concerns and outline next steps, but the announcement itself did not add new clinical results. Cullinan investor event announcement
• Negative Sentiment: The initial market response to the Phase 3 results was negative. Reports indicated that CGEM shares fell about 6.3% after the announcement, suggesting investors may have viewed the data as insufficiently compelling relative to expectations despite the six-month PFS improvement. The company’s analyst call and additional disclosures may be important for determining whether the result represents a durable catalyst. CGEM shares fall after trial results

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.